A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.
Ovarian · Breast · SCLC · Gastric Cancers
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 264 (final count)
- Started
- Mar 17, 2016
- Main results expected
- Sep 17, 2021
- Fully finished
- Sep 17, 2026
- Results posted
- Oct 13, 2023
What counts as success
The trial's main goal(s), called the “primary outcome.”
Initial Stage Cohorts: Disease Control Rate (DCR) at Week 12
Measured over: RECIST performed at baseline, at 4 weeks after first dose of olaparib monotherapy and every 8 weeks +/-7 days thereafter. Assessed until DCO 14 Jun 2019.
Second Stage Cohort: Objective Response Rate (ORR)
Measured over: RECIST performed at baseline, and every 8 weeks +/-7 days thereafter. Assessed until 17 Sep 2021.
Second Stage Cohorts: DCR at Week 24
Measured over: RECIST performed at baseline, and every 8 weeks +/-7 days thereafter. Assessed until 17 Sep 2021.
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT02734004 · record last updated 2026-07-14 · checked 2026-11-09 15:47 UTC